Author Number of patients Anticholinergic side effects Urinary tract Others
Greenfield and Ferra [8] 10 0 (0%) 0 (0infections%) 0 (0%)
Connor et al. [32] 13 2 (15.4%) 1 (7.7%) 1 (7.7%)
Kasabian et al. [6] 11 2 (18.2%) 1 (9.1%) 2 (18.2%)
Kaplinsky et al. [44] 21 7 (33.3%) 0 (0%) 0 (0%)
Painter et al. [45] 29 0 (0%) 0 (0%) 0 (0%)
Buyse et al. [46] 15 4 (26.7%) 0 (0%) 1 (6.7%)
Ferrara et al. [34] 34 6 (17.6%) 0 (0%) 0 (0%)
Guerra et al. [47] - 26 0 (0%) 3
Hayashi et al. [30] 4 0 (0%) 0 (0%) 0 (0%)
Table 5: Incidence of adverse events related to intravesical oxybutynin therapy.